A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Administered subcutaneously (s.c., under the skin) once daily.

DRUG

insulin glargine

Administered subcutaneously (s.c., under the skin) once daily.

Trial Locations (1)

Novo Nordisk Clinical Trial Call Center, Minneapolis